BNP Paribas Financial Markets Purchases New Shares in Cytek Biosciences, Inc. (NASDAQ:CTKB)

BNP Paribas Financial Markets purchased a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 208,664 shares of the company's stock, valued at approximately $1,354,000. BNP Paribas Financial Markets owned 0.16% of Cytek Biosciences as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Pacer Advisors Inc. acquired a new stake in Cytek Biosciences in the 4th quarter valued at approximately $196,000. Principal Financial Group Inc. grew its stake in shares of Cytek Biosciences by 0.7% during the 4th quarter. Principal Financial Group Inc. now owns 506,925 shares of the company's stock worth $3,290,000 after acquiring an additional 3,753 shares in the last quarter. Olympiad Research LP raised its holdings in shares of Cytek Biosciences by 51.0% in the fourth quarter. Olympiad Research LP now owns 19,601 shares of the company's stock valued at $127,000 after purchasing an additional 6,617 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Cytek Biosciences by 1.6% in the fourth quarter. Bank of New York Mellon Corp now owns 730,709 shares of the company's stock worth $4,742,000 after purchasing an additional 11,665 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in Cytek Biosciences during the fourth quarter worth $71,000. Institutional investors own 69.46% of the company's stock.

Cytek Biosciences Price Performance

NASDAQ CTKB traded down $0.03 on Friday, hitting $2.42. 914,867 shares of the stock were exchanged, compared to its average volume of 737,875. The company has a market capitalization of $306.51 million, a PE ratio of -30.25 and a beta of 1.42. The business's fifty day moving average is $3.57 and its 200 day moving average is $5.06. Cytek Biosciences, Inc. has a 52 week low of $2.37 and a 52 week high of $7.63.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.05). Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%. The firm had revenue of $41.46 million for the quarter, compared to analyst estimates of $43.18 million. Analysts predict that Cytek Biosciences, Inc. will post -0.06 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on CTKB. TD Cowen lowered shares of Cytek Biosciences from a "buy" rating to a "hold" rating and set a $4.00 price target on the stock. in a research note on Friday, May 9th. Piper Sandler decreased their price objective on Cytek Biosciences from $8.50 to $8.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Stephens reaffirmed an "overweight" rating and issued a $6.00 target price on shares of Cytek Biosciences in a research report on Wednesday, March 19th. Finally, The Goldman Sachs Group decreased their price target on Cytek Biosciences from $3.50 to $3.00 and set a "sell" rating for the company in a research note on Monday, May 12th.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.